Lei Jianping reported on April 28
Guizhou Sanli Pharmaceutical Co., Ltd. (hereinafter referred to as "Guizhou Sanli") was listed on the Shanghai Stock Exchange today, issuing 40.74 million shares at an issue price of 7.35 yuan and raising 240 million yuan.
Guizhou Sanli today's opening price is 8.82 yuan, the closing price is 10.58 yuan, the closing price is 43.95% higher than the issue price, and the market value of Guizhou Sanli is 4.309 billion yuan in terms of market value.
Zhang Hai, chairman and general manager of Guizhou Sanli, said that With the help of the A-share capital market platform, Guizhou Sanli will continue to maintain the company's position in the market of proprietary Chinese medicines and children's special drugs for throat diseases on the one hand, and strive to greatly improve the market share with the help of the A-share capital market platform, on the one hand, to continuously enhance the value of the company and maximize the interests of investors.
At present, Zhang Hai inherits his father's business for his son, and together with his mother Wang Huiying, he is the first and second largest shareholders of the company respectively. After the IPO, the two held a total of about 60% of the shares, and based on this calculation, Wang Huiying and Zhang Haimu were worth nearly 2.6 billion yuan.
Last year's net profit was 130 million yuan mainly by open throat sword spray
Guizhou Sanli is a modern proprietary Chinese medicine pharmaceutical enterprise integrating R&D, production and sales. The company's product line mainly revolves around pediatrics, respiratory system, cardiovascular and cerebrovascular medicine, gastroenterology and other fields, the main products are open throat sword spray (children's type), open throat sword spray and powerful tianma eucommia capsules.
Among them, the core products of open throat sword spray (children's type) and open throat sword spray are national patent products and market exclusive varieties, occupying a high market share in the throat disease Chinese medicine spray market, and have formed a certain brand awareness in the field of throat disease and children's proprietary Chinese medicine.
According to the statistics of the Southern Institute, open throat sword spray (including children's type) occupies the first place in the chinese medicine spray market for throat diseases, ranking 1st for 3 consecutive years, and ranking 1st in the terminal market of chinese medicine spray hospitals for throat diseases for 6 consecutive years.
In each period of the reporting period, the sales revenue of Guizhou Sanli Open Throat Sword Spray (children's type) and Open Throat Sword Spray totaled 610 million, 690 million and 850 million yuan respectively, accounting for 95.8%, 95.89% and 96.54% of the main business income, respectively.
In 2017, 2018 and 2019, guizhou Sanli's revenue was 638 million yuan, 722 million yuan and 884 million yuan, respectively, and its net profit was 87.62 million yuan, 110 million yuan and 133 million yuan, respectively.
Guizhou Sanli expects to achieve a relatively low growth rate of operating income from January to March 2020, with an expected range of 148 million yuan to 153 million yuan, an increase of 3.46% to 6.96% year-on-year; net profit attributable to shareholders of the parent company of 22 million yuan to 23 million yuan, an increase of 5.43% to 10.22% year-on-year;
Guizhou Sanli expects net profit attributable to the parent company from January to March 2020 after deducting non-recurring gains and losses of 25 million yuan to 26 million yuan, an increase of 18.38% to 23.11% year-on-year.
The actual controller, Zhang Hai, is the son who inherits his father's business
Prior to the IPO, the controlling shareholder and actual controller of Guizhou Sanli was Zhang Hai. Zhang Hai holds 18,866,844,000 shares in the Company, accounting for 51.47% of the total share capital of the Company.
Zhang Hai, born in 1985, holds a master's degree in middle school; from January 2008 to December 2009, he served as the company's sales manager in Guizhou; from January 2010 to August 2011, he served as the company's sales director; since September 2011, he has served as the chairman and general manager of the company.
Wang Huiying, born in July 1956, was an employee of Guiyang Pharmaceutical Factory from 1973 to 2005, and has been retired since 2005.
Sheng Yongjian holds 9.1% of the shares, which is a director of Guizhou Sanli, GF Securities holds 3.99%, Guiyang Industrial Investment holds 2.42%, and Shenzhen Tongchuang holds 2.34%.
After the IPO, Zhang Hai held 46.32% of the shares, and Wang Huiying held 13.65%, that is to say, Wang Huiying and Zhang Hai's mother and son held a total of 59.97% of the shares.
In fact, Guizhou Sanli was not founded by Zhang Hai, but by his father Zhang Leling. Guizhou Sanli was formerly known as Sanli Limited, which was jointly funded by Zhang Leling and Wu Liguang.
On September 30, 2011, after the deliberation and approval of the shareholders' meeting of Sanli Limited, Zhang Leling died of illness, and since then, Zhang Hai has gradually inherited the family business.
———————————————
Founded by Veteran Media Personality Lei Jianping, Lei Di Touch Network is a signed author of headlines, if reprinted, please indicate the source.